Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101836 | 0.89 | FGFR1 (0.52) | DHFRIRAK4SMN1; SMN2FGFR1KDR | |
| SCHEMBL4118866 | 0.87 | DHFR (0.50) | DHFRIRAK4SMN1; SMN2FGFR1KDR | |
| SCHEMBL4100252 | 0.85 | IRAK4 (0.49) | IRAK1DHFRIRAK4SMN1; SMN2FGFR1 | |
| SCHEMBL3978332 | 0.84 | SMN1; SMN2 (0.59) | IRAK1DHFRIRAK4SMN1; SMN2FGFR1 | |
| SCHEMBL4082424 | 0.84 | IRAK4 (0.48) | IRAK1DHFRIRAK4SMN1; SMN2KDR | |
| SCHEMBL4107262 | 0.83 | DHFR (0.50) | IRAK1DHFRIRAK4SMN1; SMN2FGFR1 | |
| SCHEMBL4107081 | 0.83 | IRAK4 (0.60) | IRAK1DHFRIRAK4SMN1; SMN2KDR | |
| SCHEMBL4113403 | 0.83 | KDR (0.48) | IRAK1DHFRIRAK4SMN1; SMN2FGFR1 | |
| SCHEMBL4110576 | 0.81 | DHFR (0.48) | IRAK1DHFRIRAK4SMN1; SMN2ADORA2A | |
| SCHEMBL4107698 | 0.81 | DHFR (0.46) | IRAK1DHFRIRAK4SMN1; SMN2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | IRAK1 1856/4885DHFR 1013/4885IRAK4 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.